October 11, 2024: We presented our public comment at the NASEM Review of CDC COVID-19 Vaccine Safety Research and Communications Meeting 3 on how CDC could improve research and communications regarding COVID-19 vaccines. We said CDC needs to be clear on what is known and not known and needs to quantify what is known about adverse events and complications from vaccines.
Read More »On Health Policy
NCHR Public Comment on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies
September 26, 2024: NCHR appreciates the improvements made in the 2024 FDA draft guidance for Diversity Action Plans but the draft lacks incentives to encourage companies to comply. The indication and label should reflect the evidence for sex, race, ethnicity, and ages of patients studied. Approval should only be for patients for whom clear evidence of safety and effectiveness was provided.
Read More »NCHR Letter for the Record for Hearing on the Consumer Product Safety Commission Budget
July 22, 2024: NCHR’s letter for the record for the House hearing: “The Fiscal Year 2025 Consumer Product Safety Commission Budget” describes the accomplishments of the CPSC and urges Congress to support CPSC’s life-saving work evaluating consumer products, especially those for children, in order to keep all of us safe.
Read More »NCHR Signed On to Letter Urging Greater Appropriations for the Consumer Product Safety Commission
NCHR and other non-profit organizations sent a letter urging increased FY 2025 appropriations for the Consumer Product Safety Commission. CPSC funding should not be subject to cuts or restrictions that would further undermine its ability to protect the public from hazardous consumer products.
Read More »NCHR Testimony at the FDA Listening Session on Advisory Committee Meetings
June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.
Read More »